Transcenta Holding Limited (6628.HK) HKSE

3.54

-0.03(-0.84%)

Updated at October 20 11:59AM

Currency In HKD

Transcenta Holding Limited

Address

B6-501, 218 Xinghu Street

Suzhou, 215123

China

Phone

86 21 6237 0929

Sector

Healthcare

Industry

Biotechnology

Employees

184

First IPO Date

September 29, 2021

Key Executives

NameTitlePayYear Born
Dr. Li Xu M.D.Head of CDx, Member of Scientific Advisory Board, Strategic Advisor to Chief Executive Officer & Non-Executive Director748,535N/A
Dr. Xueming Qian Ph.D.Executive Chairman & Chief Executive Officer1.24M1969
Dr. Caroline Germa M.D., Ph.D.Executive Vice President of Global Medicine Development & Chief Medical Officer01972
Fan ZhangSVice President of Process Development0N/A
Dr. Yi Gu Ph.D.Senior Vice President & Head of Research01969
Dr. Christopher Hwang Ph.D.Executive Vice President of Process Development & Chief Technology Officer01965
Dr. Charlie Qi M.D.Senior Vice President of Global Clinical Development0N/A
Mr. Weiwei Liang M.B.A.Acting Chief Financial Officer, Senior Vice President of Business Development Transaction & Corporate Strategy01976
Ms. Wei WangVice President of Investor Relations & Capital Markets Department and Secretary to the Board01983
Dr. Wen-I Chang Ph.D.Senior Vice President of Oncology Franchise Strategy0N/A

Description

Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People's Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric cancer and is under Phase II clinical trial; TST005, a PD-L1/TGF-ß bi-functional antibody candidate which is under Phase Ia clinical trial for solid tumors, including certain lung cancers; TST010, an antibody candidate targeting regulatory T cells to enhance T cell mediated tumor killing;TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate for IgA kidney diseases. It also develops TST003, an antibody candidate targeting a novel immune regulatory protein produced by tumor-associated fibroblasts or tumor cells with mesenchymal phenotype; TST006, a bi-specific claudin 18.2/PD-L1 antibody; TST008, a tri-functional antibody combining a MASP2 antibody fused with a truncated transmembrane activator and CAML interactor protein; MSB0254, a humanized VEGFR-2 mAb candidate for solid tumors and is under Phase Ib/IIa clinical trials; and MSB2311, A humanized PD-L1 mAb Candidate for solid tumors and is under Phase Ib/IIa clinical trials Transcenta Holding Limited has collaboration agreements with Eli Lilly and Company, Alebund Pharmaceuticals, and Merck. The company was formerly known as MabSpace International Limited and changed its name to Transcenta Holding Limited in June 2019. Transcenta Holding Limited was incorporated in 2010 and is headquartered in Suzhou, the People's Republic of China.